Posaconazole.
Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.
Bhattacharya
M
M
Department of Pediatrics, Maulana Azad Medical College & Lok Nayak Hospital, New Delhi, India.
Rajeshwari
K
K
Dhingra
B
B
D000284:Administration, Oral; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D025141:Drug Resistance, Fungal; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D016879:Salvage Therapy; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole